L-165,041
SIGMA/L2167 - ≥98% (HPLC), powder
Synonym: 4-
CAS Number: 79558-09-1
Empirical Formula (Hill Notation): C22H26O7
Molecular Weight: 402.44
MDL Number: MFCD04974501
Linear Formula: C22H26O7
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | off-white |
| form | powder |
| InChI | 1S/C22H26O7/c1-3-5-19-20( |
| InChI key | HBBVCKCCQCQCTJ-UHFFFAOYSA |
| mp | 127-128 °C (lit.) |
| originator | GlaxoSmithKline |
| Quality Level | 100 ![]() |
| SMILES string | CCCc1c(O)c(ccc1OCCCOc2ccc |
| solubility | DMSO: >10 mg/mL |
| storage condition | protect from light |
| under inert gas | |
| storage temp. | 2-8°C |
| Application: | L-165,041 has been used as a peroxisome proliferator-activated receptor β/δ (PPARβ/δ) ligand to study its influence on PPARβ/δ mediated postnatal myogenesis in C2C12 myoblasts. |
| Biochem/physiol Actions: | L-165041 dose-dependently blocks rat vascular smooth muscle cell (VSMC) proliferation and migration by inducing the cell cycle arrest. It has the potential to treat pathological cardiovascular conditions, such as restenosis and atherosclerosis. L-165041 also effectively inhibits the progression of diabetic nephropathy. It exhibits anti-apoptosis and anti-angiogenic effects. |
| Biochem/physiol Actions: | PPARβ (PPARδ) selective agonist. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| mp | 127-128 °C (lit.) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |

